

AMENDMENTS

In the claims:

Claims 1-46 (Cancelled).

47. (Currently amended) A nucleic acid molecule encoding ~~a CEA molecule~~ **consisting of** an amino acid sequence **consisting of a sequence** selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5.
48. (Previously presented) A vector comprising the nucleic acid of claim 47.
49. (Previously presented) The vector of claim 48, wherein the vector is selected from the group consisting of *E. coli* plasmid, *Listeria* vector, orthopox virus, avipox virus, capripox virus, suipox virus, vaccinia virus, baculovirus, human adenovirus, SV40 virus and bovine papilloma virus.
50. (Previously presented) The vector of claim 49 further comprising a nucleotide sequence encoding at least one HLA class I molecule.
51. (Cancelled).
52. (Previously presented) A kit comprising the vector of claim 48.
53. (Currently amended) A kit comprising an **a CEA** agonist peptide and a vector comprising a gene encoding CEA or a recombinantly produced CEA protein and an immunostimulatory molecule.
54. (Currently amended) The kit according to claim ~~52~~ **53**, wherein said ~~vector~~ **comprises a nucleic acid comprising the nucleic acid sequence encoding agonist peptide** is SEQ ID NO: 2.
55. (Cancelled).

- 56. ~~56.~~(Currently amended) The vector of claim 50, wherein the HLA class I molecule is HLA-A2.
- 57. (Cancelled).
- 58. (Previously presented) A composition comprising the nucleic acid molecule of claim 47.
- 59. (Previously presented) The composition of claim 58, which is capable of stimulating a CEA specific cytolytic cytotoxic T lymphocyte (CTL) response in a subject.